Clinical trial
Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network
NCT03221166 is registered in ClinicalTrials.gov with IRCCS Burlo Garofolo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network
- Lead sponsor
- IRCCS Burlo Garofolo
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- February 27, 2018
- Completion date
- July 31, 2020
- Enrollment
- 9 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.